(19)
(11) EP 0 514 130 A3

(12) EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
21.07.1993 Bulletin 1993/29

(43) Date of publication A2:
19.11.1992 Bulletin 1992/47

(21) Application number: 92304260.0

(22) Date of filing: 12.05.1992
(51) International Patent Classification (IPC)5: A61K 37/02
(84) Designated Contracting States:
CH DE FR GB IT LI NL

(30) Priority: 13.05.1991 US 699092

(71) Applicants:
  • MERCK & CO. INC.
    Rahway New Jersey 07065-0900 (US)
  • CURATORS OF THE UNIVERSITY OF MISSOURI
    Columbia, MO 65211 (US)

(72) Inventors:
  • Sato, Masahiko
    Lansdale, PA 19446 (US)
  • Gorski, Jeffrey P.
    Prairie Village, Kansas (US)
  • Rodan, Gideon A.
    Bryn Mawr, PA 19010 (US)

(74) Representative: Thompson, John Dr. et al
Merck & Co., Inc. European Patent Department Terlings Park Eastwick Road
Harlow, Essex CM20 2QR
Harlow, Essex CM20 2QR (GB)


(56) References cited: : 
   
       


    (54) Bone acidic glycoprotein (BAG-75) for inhibiting bone resorption


    (57) Disclosed is a new method for treating bone disease in mammals, which is associated with increased bone resorption activity (dissolution or breakdown), and involves the new use and administration of known bone acidic glycoproteins 75 (BAG 75), having a molecular weight of 75kDa as determined by SDS-PAGE, or the 50kDa (SDS-PAGE) fragment thereof, wherein BAG 75 contains an N-terminal sequence of :
    (SEQ. ID NO. 1), (LPVARYQNTEEEE). The method is applicable and indicated for osteoporosis, Paget's disease, hyperparathyroidism, hypercalcemia of malignancy, osteopenia due to bone metastases, bone loss due to immobilization, sex hormone deficiency, glucocorticoid treatment, periodontal disease, and periarticular erosion in rheumatoid arthritis.









    Search report